解决了传统柔性电极在大脑中易移位、易脱出的核心痛点。 作者丨杨婧雪 编辑丨刘恒涛 2月11日，侵入式柔性电极脑机接口公司智冉医疗宣布完成A+轮融资，本轮融资金额达3亿元，由中 科创星领投，老股东君联资本、北京市医药健康产业投资基金、IDG资本、顺为资本、联想创投、元 生创投、红杉中国、美团龙珠、BV百度风投、杏泽资本、佳银资本持续跟投。据悉，本轮融资将主要 用于推进大规模临床试验与高通量柔性脑机接口产品迭代，加速该技术向临床应用落地。 | | | 北京智冉医疗科技有限公司--融资历程 | | | | --- | --- | --- | --- | --- | | 融资轮次 | 事件时间 | 融资金额 | 估值/市值 | 投资方 | | | | | | 中科创星领投 BV百度风投 | | | | | | IDG资本 | | | | | | 佳银基金 | | | | | | 顺禧基金 | | A+轮 | 2026年2月11日 | 3亿人民币 | 未披露 | 君联资本 Legend Capital | | | | | | 元生创投 | | | | | | 美团龙珠 | | | | | | 联想创投 | | | | ...

一开年，马斯克放出豪言：旗下脑机接口公司Neuralink将2026年大规模设备量产，引发全球股市上涨。 这边，被看作Neuralink最大对手的强脑科技，也迅速完成20亿元融资，并传出以保密形式递交港股IPO 申请。 而股民们最关心的A股，也没有被这股风口落下，即将迎来脑机接口第一股。 近日，脑机接口公司博睿康在上海证监局办理辅导备案登记，冲刺科创板上市。 博睿康核心团队来自清华大学，由红杉中国、百度风投等知名机构押注。 - 01 - 博睿康创始人胥红来生于1979年，本科、硕士、博士都就读于清华大学生物医学工程专业。硕博期间， 胥红来的导师是国际脑机接口学会唯一的国内理事高上凯。 2010 年，第一届中国脑机接口比赛上，胥红来看到，不管是高校代表队还是科研机构，手里的核心设 备清一色都是进口的。比赛结束后，中科院有位研究员给高上凯老师写了一封信。他在信中问，脑机接 口用到的设备全靠进口，以后还怎么产业化，成本又怎么降下来？ 2011年，胥红来拉上同系博士黄肖山创办博睿康。北京创业成本太高，团队把目光投向了常州 —— 这 里的科教城给政策、给孵化基金，连前期厂房都帮着协调。2011年11月，博睿康落地常州， ...

Company Overview - Brain-computer interface company, BoRuiKang Technology (Shanghai) Co., Ltd., has completed its IPO counseling registration on February 4, 2026, with CITIC Securities as the counseling broker, marking the official start of its Sci-Tech Innovation Board IPO process [1][2][3] - Established in November 2011, BoRuiKang's core team includes experts from Tsinghua University's Neural Engineering Laboratory and clinical neuroscience, focusing on the research, production, and technical services of brain-computer interface systems [3][4] - The company has developed products for clinical diagnosis and research education, including digital EEG machines and transcranial electrical stimulation systems, with some products already receiving medical device registration [3][4] Product Development - BoRuiKang's flagship product, the NEO wireless minimally invasive brain-computer interface system, is the world's first to use an epidural implant with fully wireless transmission design [3][4] - NEO employs a "semi-invasive" technique, implanting coin-sized electrodes beneath the skull but outside the dura mater, allowing proximity to neurons without direct contact, thus avoiding damage to neural tissue [4] - The NEO system has undergone successful clinical trials, with 32 patients having completed implantation across 11 hospitals, achieving a 100% success rate in primary clinical endpoints [4][5] Regulatory Progress - NEO is set to submit a Class III innovative medical device registration application to the National Medical Products Administration, potentially becoming the first marketed implantable brain-computer interface product in China [5] - The product's first version, NEO 1.0, is expected to be followed by a 2.0 version that will include additional features such as language decoding and small limb decoding [5] Financial Backing and Valuation - BoRuiKang has completed multiple rounds of financing, with notable investors including Sequoia China and Baidu Ventures, achieving a post-investment valuation of 3.5 to 4 billion yuan by the end of 2025 [5][6] - The company has raised a total of 1.2 million yuan in angel funding and 30 million yuan in Pre-A funding, among other financing rounds [5] Industry Context - The brain-computer interface industry is experiencing significant growth opportunities in China, supported by favorable policies and market conditions [9][10] - The Ministry of Industry and Information Technology and other departments have included brain-computer interfaces in key future industry cultivation, with projections indicating the market could exceed 120 billion yuan by 2040 [10]

Group 1: Neuralink's Developments - Neuralink has showcased its latest research achievements and future plans through a one-hour video, highlighting the capabilities of its N1 chip for controlling devices with thoughts [2] - The N1 chip, the size of a coin, features 1024 electrodes that capture brain signals in real-time and convert them into digital commands, with seven subjects currently implanted [2][3] - Future plans include increasing electrode counts to 3,000 by 2026, 10,000 by 2027, and over 25,000 by 2028, aiming to treat mental disorders and enhance human-machine interaction [3] Group 2: Market Potential and Growth - The brain-computer interface (BCI) industry is recognized as a groundbreaking field with significant potential across medical, technological, and entertainment sectors [4][6] - The global BCI market size has grown from $1.2 billion in 2019 to $2 billion in 2023, with a compound annual growth rate (CAGR) exceeding 13% [6] - By 2029, the global BCI industry is projected to reach $7.63 billion, indicating strong growth despite current clinical trial limitations and ethical challenges [7] Group 3: China's BCI Industry - China has over a hundred companies with products in clinical stages, with leading firms including Pinchi Medical and Zhejiang Yiyang focusing on various BCI applications [9][10] - The aging population and high prevalence of neurological diseases in China create a robust market demand for BCI technologies, with expectations for the industry to exceed 10 billion yuan by 2029 [10]

Core Insights - The brain-computer interface (BCI) sector is experiencing significant advancements, with various developments in policy, clinical applications, and technology integration [1][4][6] Policy Developments - Sichuan province has launched a comprehensive action plan for brain-computer interface and human-computer interaction industries from 2025 to 2030, aiming to develop multiple BCI products and enhance clinical applications [4][5] - National policies are being introduced to support the development of BCI technology, including quality requirements for medical devices using BCI technology and guidelines for pricing new neuro-related medical services [4][5] Market Potential - The global BCI market is projected to reach $3.3 billion by 2027, with a compound annual growth rate (CAGR) of approximately 13.5% since 2019 [2] - In China, the BCI market is expected to grow to 3.2 billion yuan in 2024, with an annual growth rate of 18.8%, and is forecasted to exceed 5.5 billion yuan by 2027 [3] Clinical Applications - BCI technology is being applied in various medical fields, particularly in treating cognitive and motor disorders, with significant clinical trials underway [6][8] - The first clinical ward for BCI technology has been established at Beijing Tiantan Hospital, focusing on research and clinical trials [6] Technological Integration - Synchron has partnered with Apple to integrate its BCI device with Apple products, allowing users to control devices using only their thoughts [7] - Neuralink's BCI device has received "breakthrough medical device" designation from the FDA, targeting patients with severe neurological conditions [7][8] Future Outlook - The BCI industry is expected to continue evolving, with increasing clinical applications and technological advancements, although challenges related to safety, ethics, and privacy remain [8]